Soley Therapeutics Secures $200M Series C, Propelling AI-Driven Oncology and Neurodegenerative Programs to Clinic
January 11, 2026, 3:38 am
Soley Therapeutics locked in $200 million in Series C funding. This major capital injection drives two oncology programs into clinical development, focusing on acute myeloid leukemia (AML) and solid tumors. The funds also support non-oncology assets for neurodegenerative disorders and metabolic diseases. It further scales Soley's proprietary AI and computer vision-enabled cell stress-sensing platform. This significant investment positions the biotech firm for rapid advancement in precision drug discovery and clinical trials.
Soley Therapeutics announced a significant financial milestone. The South San Francisco-based biotech secured $200 million in Series C funding. This substantial capital infusion will accelerate the company's pioneering work. It marks a critical juncture for Soley's innovative drug discovery pipeline. Investor confidence remains high for the firm's AI-powered approach.
The Series C round saw strong participation. Surveyor Capital led the investment as the primary new backer. New investors included HRTG Partners and RWN Management. Existing supporters also reaffirmed their commitment. The Doug Leone Family Fund, Breyer Capital, and GordonMD Global Investment® LP were key returning investors. This blend of new and established support underscores Soley's market appeal. It validates their technology and strategic vision.
Proceeds from this funding are earmarked for critical initiatives. A primary focus is advancing two internally discovered oncology programs. These represent first-in-class therapeutic candidates. One lead asset targets Acute Myeloid Leukemia (AML). Its Investigational New Drug (IND) filing is planned for 2026. A second asset focuses on solid tumors. This program will enter IND-enabling studies soon. These steps are vital for bringing new treatments to patients.
Soley's pipeline extends beyond oncology. The funding will also support non-oncology drug candidates. These stress-reducing therapies target debilitating conditions. Neurodegenerative disorders are a key area of focus. Metabolic diseases also feature prominently in the company's efforts. This diversified approach demonstrates the platform's broad applicability. It addresses significant unmet medical needs across various disease areas.
At the heart of Soley's innovation lies its cell stress-sensing platform. This proprietary technology is truly cutting-edge. It precisely measures time-resolved cellular responses. Thousands of features are analyzed within human cells. The platform employs advanced computer vision. It uses artificial intelligence (AI) to interpret complex cellular signals. These signals transform into structured, actionable signatures. This deep insight into cellular behavior underpins Soley's drug discovery.
The platform's capabilities are extensive. It screens hundreds of thousands of compounds weekly. This high-throughput capacity is crucial for rapid identification of drug candidates. In-house automation and robotics ensure reproducible data generation at scale. This robust data forms the basis for machine learning models. Soley trains proprietary AI/ML models. These models accelerate hit discovery. They generate mechanistic insights. They also facilitate molecule design. This systematic, data-driven approach streamlines the drug development process.
Soley further strengthened its AI infrastructure in March 2025. Strategic collaborations with tech giants Oracle and Nvidia were established. These partnerships enhance the platform's computational power. They expand its analytical capabilities. Access to leading AI and cloud technologies provides a significant competitive advantage. It allows Soley to push the boundaries of AI in drug discovery.
The biotech landscape increasingly relies on advanced technologies. AI and machine learning are transforming how new drugs are found. Soley Therapeutics exemplifies this shift. Its platform offers a unique window into cellular health and disease. It predicts how cells respond to drug exposure. This precision guides the development of highly targeted therapies. This approach minimizes guesswork and optimizes development pathways.
This $200 million investment underscores the growing interest in AI-powered biotechnology. Investors see immense potential in platforms that de-risk drug development. Soley's ability to generate reproducible data at scale is a major draw. Its focus on first-in-class assets in critical disease areas is equally appealing. The capital secures the necessary resources for ambitious clinical plans. It solidifies Soley's position as an emerging leader.
The company's strategic location in South San Francisco is beneficial. This area is a global hub for biotechnology innovation. Proximity to top talent, research institutions, and a robust biotech ecosystem fosters growth. It facilitates collaborations and access to specialized expertise. This environment is ideal for a company engaged in advanced drug discovery.
Looking forward, Soley Therapeutics aims for swift clinical progress. The IND filings and trial initiations are paramount. Successful clinical development could yield transformative therapies. These new drugs could significantly improve patient outcomes. They address diseases with limited treatment options. The company's vision is clear: to translate cellular insights into life-changing medicines. The Series C funding provides the fuel for this mission. It signals a new era for Soley Therapeutics and its impact on precision medicine.
Soley Therapeutics announced a significant financial milestone. The South San Francisco-based biotech secured $200 million in Series C funding. This substantial capital infusion will accelerate the company's pioneering work. It marks a critical juncture for Soley's innovative drug discovery pipeline. Investor confidence remains high for the firm's AI-powered approach.
The Series C round saw strong participation. Surveyor Capital led the investment as the primary new backer. New investors included HRTG Partners and RWN Management. Existing supporters also reaffirmed their commitment. The Doug Leone Family Fund, Breyer Capital, and GordonMD Global Investment® LP were key returning investors. This blend of new and established support underscores Soley's market appeal. It validates their technology and strategic vision.
Proceeds from this funding are earmarked for critical initiatives. A primary focus is advancing two internally discovered oncology programs. These represent first-in-class therapeutic candidates. One lead asset targets Acute Myeloid Leukemia (AML). Its Investigational New Drug (IND) filing is planned for 2026. A second asset focuses on solid tumors. This program will enter IND-enabling studies soon. These steps are vital for bringing new treatments to patients.
Soley's pipeline extends beyond oncology. The funding will also support non-oncology drug candidates. These stress-reducing therapies target debilitating conditions. Neurodegenerative disorders are a key area of focus. Metabolic diseases also feature prominently in the company's efforts. This diversified approach demonstrates the platform's broad applicability. It addresses significant unmet medical needs across various disease areas.
At the heart of Soley's innovation lies its cell stress-sensing platform. This proprietary technology is truly cutting-edge. It precisely measures time-resolved cellular responses. Thousands of features are analyzed within human cells. The platform employs advanced computer vision. It uses artificial intelligence (AI) to interpret complex cellular signals. These signals transform into structured, actionable signatures. This deep insight into cellular behavior underpins Soley's drug discovery.
The platform's capabilities are extensive. It screens hundreds of thousands of compounds weekly. This high-throughput capacity is crucial for rapid identification of drug candidates. In-house automation and robotics ensure reproducible data generation at scale. This robust data forms the basis for machine learning models. Soley trains proprietary AI/ML models. These models accelerate hit discovery. They generate mechanistic insights. They also facilitate molecule design. This systematic, data-driven approach streamlines the drug development process.
Soley further strengthened its AI infrastructure in March 2025. Strategic collaborations with tech giants Oracle and Nvidia were established. These partnerships enhance the platform's computational power. They expand its analytical capabilities. Access to leading AI and cloud technologies provides a significant competitive advantage. It allows Soley to push the boundaries of AI in drug discovery.
The biotech landscape increasingly relies on advanced technologies. AI and machine learning are transforming how new drugs are found. Soley Therapeutics exemplifies this shift. Its platform offers a unique window into cellular health and disease. It predicts how cells respond to drug exposure. This precision guides the development of highly targeted therapies. This approach minimizes guesswork and optimizes development pathways.
This $200 million investment underscores the growing interest in AI-powered biotechnology. Investors see immense potential in platforms that de-risk drug development. Soley's ability to generate reproducible data at scale is a major draw. Its focus on first-in-class assets in critical disease areas is equally appealing. The capital secures the necessary resources for ambitious clinical plans. It solidifies Soley's position as an emerging leader.
The company's strategic location in South San Francisco is beneficial. This area is a global hub for biotechnology innovation. Proximity to top talent, research institutions, and a robust biotech ecosystem fosters growth. It facilitates collaborations and access to specialized expertise. This environment is ideal for a company engaged in advanced drug discovery.
Looking forward, Soley Therapeutics aims for swift clinical progress. The IND filings and trial initiations are paramount. Successful clinical development could yield transformative therapies. These new drugs could significantly improve patient outcomes. They address diseases with limited treatment options. The company's vision is clear: to translate cellular insights into life-changing medicines. The Series C funding provides the fuel for this mission. It signals a new era for Soley Therapeutics and its impact on precision medicine.